| Year |
Citation |
Score |
| 2019 |
Stacy M, Sajatovic M, Kane JM, Cutler AJ, Liang GS, O'Brien CF, Correll CU. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31234240 DOI: 10.1002/Mds.27769 |
0.322 |
|
| 2019 |
Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Cns Spectrums. 1-2. PMID 31182180 DOI: 10.1017/S1092852919000932 |
0.393 |
|
| 2018 |
Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Cns Spectrums. 23: 402-413. PMID 30588905 DOI: 10.1017/S1092852918001359 |
0.36 |
|
| 2018 |
Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F. The spectrum of "off" in Parkinson's disease: What have we learned over 40 years? Parkinsonism & Related Disorders. PMID 29456046 DOI: 10.1016/J.Parkreldis.2018.02.001 |
0.413 |
|
| 2017 |
Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitch D, Stacy MA. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28646494 DOI: 10.1002/Mds.27092 |
0.444 |
|
| 2017 |
Hickey PT, Kuchibhatla M, Scott B, Gauger L, Stacy MA. Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson's Disease. Journal of Parkinson's Disease. PMID 28339403 DOI: 10.3233/Jpd-160937 |
0.485 |
|
| 2016 |
Hickey P, Stacy M. Deep brain stimulation: a paradigm shifting approach to treat Parkinson's disease Frontiers in Neuroscience. 10: 173-173. PMID 27199637 DOI: 10.3389/Fnins.2016.00173 |
0.442 |
|
| 2016 |
Cooney JW, Stacy M. Neuropsychiatric Issues in Parkinson's Disease. Current Neurology and Neuroscience Reports. 16: 49. PMID 27048443 DOI: 10.1007/S11910-016-0647-4 |
0.422 |
|
| 2015 |
Park A, Stacy M. Disease-Modifying Drugs in Parkinson's Disease. Drugs. PMID 26581672 DOI: 10.1007/S40265-015-0497-4 |
0.497 |
|
| 2015 |
Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Annals of Neurology. 78: 248-57. PMID 26061140 DOI: 10.1002/Ana.24436 |
0.583 |
|
| 2015 |
Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, Manack Adams A, Brin MF. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). Journal of the Neurological Sciences. 349: 84-93. PMID 25595221 DOI: 10.1016/J.Jns.2014.12.030 |
0.33 |
|
| 2015 |
Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 121-7. PMID 25370355 DOI: 10.1002/Mds.26016 |
0.476 |
|
| 2014 |
Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, Stacy M, Murrell JR, Ozelius LJ, Brashear A, Ghetti B. Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. Acta Neuropathologica. 128: 81-98. PMID 24803225 DOI: 10.1007/S00401-014-1279-X |
0.344 |
|
| 2014 |
Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, ... ... Stacy MA, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. Jama Neurology. 71: 543-52. PMID 24664227 DOI: 10.1001/Jamaneurol.2014.131 |
0.438 |
|
| 2014 |
Cook JF, Hill DF, Snively BM, Boggs N, Suerken CK, Haq I, Stacy M, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A. Cognitive impairment in rapid-onset dystonia-parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 344-50. PMID 24436111 DOI: 10.1002/Mds.25790 |
0.32 |
|
| 2014 |
Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, ... ... Stacy MA, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. Jama Neurology. 71: 141-50. PMID 24366103 DOI: 10.1001/Jamaneurol.2013.5528 |
0.463 |
|
| 2013 |
Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1838-46. PMID 23853029 DOI: 10.1002/Mds.25561 |
0.445 |
|
| 2013 |
Barker RA, Stacy M, Brundin P. A new approach to disease-modifying drug trials in Parkinson's disease. The Journal of Clinical Investigation. 123: 2364-5. PMID 23728166 DOI: 10.1172/Jci69690 |
0.365 |
|
| 2013 |
Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, Turner DA, Stacy M, Lang AE, Lozano AM, Olanow CW. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 80: 1698-701. PMID 23576625 DOI: 10.1212/Wnl.0B013E3182904Faa |
0.632 |
|
| 2013 |
Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O'Connell M, Gupta S. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. The Lancet. Neurology. 12: 346-56. PMID 23485610 DOI: 10.1016/S1474-4422(13)70025-5 |
0.381 |
|
| 2013 |
Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S. Which dyskinesia scale best detects treatment response? Movement Disorders : Official Journal of the Movement Disorder Society. 28: 341-6. PMID 23390076 DOI: 10.1002/Mds.25321 |
0.378 |
|
| 2013 |
Hickey P, Stacy M. AAV2-neurturin (CERE-120) for Parkinson's disease Expert Opinion On Biological Therapy. 13: 137-145. PMID 23228025 DOI: 10.1517/14712598.2013.754420 |
0.5 |
|
| 2013 |
Boland DF, Stacy M. The economic and quality of life burden associated with Parkinson's disease: a focus on symptoms. The American Journal of Managed Care. 18: S168-75. PMID 23039865 |
0.373 |
|
| 2012 |
Hattori N, Fujimoto K, Kondo T, Murata M, Stacy M. Patient perspectives on Parkinson’s disease therapy in Japan and the United States: results of two patient surveys Patient Related Outcome Measures. 3: 31-38. PMID 23204876 DOI: 10.2147/Prom.S29443 |
0.346 |
|
| 2012 |
Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L, Boggs N, Suerken CK, Stacy M, Ozelius L, Sweadner KJ, McCall WV. Psychiatric disorders in rapid-onset dystonia-parkinsonism. Neurology. 79: 1168-73. PMID 22933743 DOI: 10.1212/Wnl.0B013E3182698D6C |
0.396 |
|
| 2012 |
Hickey P, Stacy M. Adenosine A2A Antagonists in Parkinson’s Disease: What’s Next? Current Neurology and Neuroscience Reports. 12: 376-385. PMID 22585137 DOI: 10.1007/S11910-012-0279-2 |
0.498 |
|
| 2012 |
Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, Stacy M, Ozelius L, Sweadner KJ, Brashear A. New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. Parkinsonism & Related Disorders. 18: 737-41. PMID 22534615 DOI: 10.1016/J.Parkreldis.2012.03.020 |
0.378 |
|
| 2012 |
Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease Expert Opinion On Pharmacotherapy. 13: 111-114. PMID 22149371 DOI: 10.1517/14656566.2012.643869 |
0.495 |
|
| 2012 |
Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism & Related Disorders. 18: 178-84. PMID 22000279 DOI: 10.1016/J.Parkreldis.2011.09.023 |
0.446 |
|
| 2012 |
Brashear A, Cook J, Amponsah A, Hill D, Snively B, Light L, Suerken C, McCall WV, Boggs N, Stacy M, Ozelius L, Sweadner K. Psychiatric and Neurocognitive Morbidity in Rapid-Onset Dystonia Parkinsonism (P01.225) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P01.225 |
0.354 |
|
| 2011 |
Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, Sutch SM, Brin MF, Papapetropoulos S. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). Bmc Neurology. 11: 140. PMID 22054223 DOI: 10.1186/1471-2377-11-140 |
0.323 |
|
| 2011 |
Stacy M. Nonmotor Symptoms in Parkinson's Disease International Journal of Neuroscience. 121: 9-17. PMID 22035025 DOI: 10.3109/00207454.2011.620196 |
0.419 |
|
| 2011 |
Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG. Wearing-off scales in Parkinson's disease: critique and recommendations. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2169-75. PMID 21780180 DOI: 10.1002/Mds.23875 |
0.396 |
|
| 2011 |
Hickey P, Stacy M. Available and emerging treatments for Parkinson's disease: a review. Drug Design Development and Therapy. 5: 241-254. PMID 21607020 DOI: 10.2147/Dddt.S11836 |
0.441 |
|
| 2011 |
Park A, Stacy M. Dopamine-induced nonmotor symptoms of Parkinson's disease. Parkinson's Disease. 2011: 485063-485063. PMID 21603184 DOI: 10.4061/2011/485063 |
0.422 |
|
| 2011 |
Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, Weintraub D, Wunderlich GR, Stacy M. Impulse control disorders in Parkinson disease: a multicenter case--control study. Annals of Neurology. 69: 986-96. PMID 21416496 DOI: 10.1002/Ana.22356 |
0.461 |
|
| 2011 |
Hickey P, Stacy M. The surgical management of Parkinson’s disease Neurodegenerative Disease Management. 1: 203-215. DOI: 10.2217/Nmt.11.25 |
0.506 |
|
| 2010 |
Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Annals of Neurology. 68: 963-8. PMID 21154480 DOI: 10.1002/Ana.22164 |
0.479 |
|
| 2010 |
Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. The Lancet. Neurology. 9: 1164-72. PMID 20970382 DOI: 10.1016/S1474-4422(10)70254-4 |
0.632 |
|
| 2010 |
Stacy M. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease Journal of Neural Transmission. 117: 837-846. PMID 20563826 DOI: 10.1007/S00702-010-0424-5 |
0.441 |
|
| 2010 |
Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Movement Disorders. 25: 927-931. PMID 20461810 DOI: 10.1002/Mds.23040 |
0.482 |
|
| 2010 |
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology. 67: 589-95. PMID 20457959 DOI: 10.1001/Archneurol.2010.65 |
0.466 |
|
| 2010 |
Stacy MA, Murck H, Kroenke K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy Progress in Neuro-Psychopharmacology and Biological Psychiatry. 34: 57-61. PMID 19793544 DOI: 10.1016/J.Pnpbp.2009.09.023 |
0.455 |
|
| 2009 |
Stacy M. Impulse control disorders in Parkinson's disease. F1000 Medicine Reports. 1: 329-330. PMID 20948752 DOI: 10.3410/M1-29 |
0.378 |
|
| 2009 |
Park A, Stacy M. Non-motor symptoms in Parkinson’s disease Journal of Neurology. 256: 293-298. PMID 19711119 DOI: 10.1007/S00415-009-5240-1 |
0.403 |
|
| 2009 |
Shill HA, Stacy M. Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatric Disease and Treatment. 5: 33-6. PMID 19557097 |
0.357 |
|
| 2009 |
Stacy M. Medical treatment of Parkinson disease. Neurologic Clinics. 27: 605-631. PMID 19555824 DOI: 10.1016/J.Ncl.2009.04.009 |
0.492 |
|
| 2009 |
Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 1561-70. PMID 19526584 DOI: 10.1002/Mds.22505 |
0.359 |
|
| 2009 |
Shill HA, De La Vega FJ, Samanta J, Stacy M. Motor learning in essential tremor. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 926-8. PMID 19243062 DOI: 10.1002/Mds.22479 |
0.317 |
|
| 2009 |
Kuncel AM, Turner DA, Ozelius LJ, Greene PE, Grill WM, Stacy MA. Myoclonus and tremor response to thalamic deep brain stimulation parameters in a patient with inherited myoclonus-dystonia syndrome. Clinical Neurology and Neurosurgery. 111: 303-6. PMID 19081669 DOI: 10.1016/J.Clineuro.2008.10.015 |
0.306 |
|
| 2009 |
Wingo TS, Evatt M, Scott B, Freeman A, Stacy M. Impulse control disorders arising in 3 patients treated with rotigotine. Clinical Neuropharmacology. 32: 59-62. PMID 18978496 DOI: 10.1097/Wnf.0B013E3181684542 |
0.406 |
|
| 2009 |
Marks W, Bartus R, Siffert J, Starr P, Ostrem J, Stacy M, Boulis N, Vitek J, Verhagen L, Watts R, Jankovic J, Tagliati M, Stern M, Nutt J, Kordower J, et al. P2.113 Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD) Parkinsonism & Related Disorders. 15: S120. DOI: 10.1016/S1353-8020(09)70464-X |
0.637 |
|
| 2008 |
Sommer DB, Stacy MA. What's in the pipeline for the treatment of Parkinson's disease? Expert Review of Neurotherapeutics. 8: 1829-1839. PMID 19086879 DOI: 10.1586/14737175.8.12.1829 |
0.483 |
|
| 2008 |
Ferrara JM, Stacy M. Impulse-control disorders in Parkinson's disease Cns Spectrums. 13: 690-698. PMID 18704024 DOI: 10.1017/S1092852900013778 |
0.464 |
|
| 2008 |
Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 70: 2233-40. PMID 18519872 DOI: 10.1212/01.Wnl.0000313834.22171.17 |
0.385 |
|
| 2008 |
Stacy M, Galbreath A. Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia. Clinical Neuropharmacology. 31: 120-125. PMID 18382184 DOI: 10.1097/Wnf.0B013E318065B09C |
0.453 |
|
| 2008 |
Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. Bmc Neurology. 8: 6. PMID 18373838 DOI: 10.1186/1471-2377-8-6 |
0.381 |
|
| 2008 |
Stacy M, Do AG. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Clinical Neuropharmacology. 31: 51-56. PMID 18303491 DOI: 10.1097/Wnf.0B013E318065B088 |
0.488 |
|
| 2008 |
Stacy M, Silver D. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. Parkinsonism & Related Disorders. 14: 85-92. PMID 18083605 DOI: 10.1016/J.Parkreldis.2007.07.016 |
0.527 |
|
| 2008 |
Kulkarni AS, Balkrishnan R, Anderson RT, Edin HM, Kirsch J, Stacy MA. Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 359-65. PMID 18074366 DOI: 10.1002/Mds.21831 |
0.45 |
|
| 2008 |
Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism & Related Disorders. 14: 205-12. PMID 17900967 DOI: 10.1016/J.Parkreldis.2007.07.013 |
0.413 |
|
| 2008 |
Shill HA, Stacy M. Update on ropinirole in the treatment of Parkinson’s disease Neuropsychiatric Disease and Treatment. 5: 33-36. DOI: 10.2147/Ndt.S3237 |
0.396 |
|
| 2007 |
Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease Expert Opinion On Pharmacotherapy. 8: 1941-1950. PMID 17696795 DOI: 10.1517/14656566.8.12.1941 |
0.431 |
|
| 2007 |
Jankovic J, Stacy M. Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson's Disease Cns Drugs. 21: 677-692. PMID 17630819 DOI: 10.2165/00023210-200721080-00005 |
0.428 |
|
| 2007 |
Galpern WR, Stacy M. Management of impulse control disorders in Parkinson's disease. Current Treatment Options in Neurology. 9: 189-97. PMID 17445496 DOI: 10.1007/Bf02938408 |
0.519 |
|
| 2007 |
Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Archives of Neurology. 64: 576-80. PMID 17420321 DOI: 10.1001/Archneur.64.4.576 |
0.359 |
|
| 2007 |
Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 68: 1108-15. PMID 17404192 DOI: 10.1212/01.Wnl.0000258660.74391.C1 |
0.492 |
|
| 2007 |
Chou KL, Stacy MA. Skin rash associated with Sinemet does not equal levodopa allergy. Neurology. 68: 1078-1079. PMID 17389317 DOI: 10.1212/01.Wnl.0000257823.27573.3D |
0.376 |
|
| 2007 |
Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1061-8. PMID 17266092 DOI: 10.1002/Mds.21382 |
0.445 |
|
| 2007 |
Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T, Shults C, Marshall F, Oakes D, Shinaman A, Marder K, Conneally PM, ... ... Stacy M, et al. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation Movement Disorders. 22: 254-257. PMID 17149721 DOI: 10.1002/Mds.21233 |
0.421 |
|
| 2007 |
Stacy M, Hauser R. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease. Journal of Neural Transmission. 114: 211-217. PMID 16897594 DOI: 10.1007/S00702-006-0554-Y |
0.399 |
|
| 2006 |
Stacy M, Hauser R, Oertel W, Schapira A, Sethi KD, Stocchi F, Tolosa E. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clinical Neuropharmacology. 29: 312-321. PMID 17095894 DOI: 10.1097/01.Wnf.0000232277.68501.08 |
0.431 |
|
| 2006 |
Kolls BJ, Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clinical Neuropharmacology. 29: 292-301. PMID 16960475 DOI: 10.1097/01.Wnf.0000220824.57769.E5 |
0.452 |
|
| 2006 |
Hancock DB, Martin ER, Fujiwara K, Stacy MA, Scott BL, Stajich JM, Jewett R, Li YJ, Hauser MA, Vance JM, Scott WK. NOS2A and the modulating effect of cigarette smoking in Parkinson's disease. Annals of Neurology. 60: 366-73. PMID 16823855 DOI: 10.1002/Ana.20915 |
0.364 |
|
| 2006 |
Lang AE, Langston JW, Stoessl AJ, Brodsky M, Brooks DJ, Dhawan V, Elias WJ, Lozano AM, Moro E, Nutt JG, Stacy M, Turner D, Wooten GF. GDNF in treatment of Parkinson's disease: response to editorial. The Lancet. Neurology. 5: 200-2. PMID 16488373 DOI: 10.1016/S1474-4422(06)70359-3 |
0.302 |
|
| 2006 |
Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 66: 672-7. PMID 16436648 DOI: 10.1212/01.Wnl.0000200779.03748.0F |
0.346 |
|
| 2006 |
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, ... Stacy M, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology. 59: 459-66. PMID 16429411 DOI: 10.1002/Ana.20737 |
0.342 |
|
| 2006 |
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, ... Stacy M, et al. Erratum: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease (Annals of Neurology (2006) 59 (459-466)) Annals of Neurology. 60. DOI: 10.1002/Ana.21061 |
0.378 |
|
| 2005 |
Karamohamed S, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, Liu J, Shoemaker CM, Wilk JB, et al. Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 1188-91. PMID 15966003 DOI: 10.1002/Mds.20515 |
0.434 |
|
| 2005 |
Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, LeWitt P, Oertel W, Quinn N, Sethi K, Stocchi F. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 726-33. PMID 15719426 DOI: 10.1002/Mds.20383 |
0.486 |
|
| 2005 |
Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM. Family-based case-control study of cigarette smoking and Parkinson disease Neurology. 64: 442-447. PMID 15699372 DOI: 10.1212/01.Wnl.0000150905.93241.B2 |
0.368 |
|
| 2005 |
Kolls BJ, Stacy M. Apomorphine: an overview of clinical use Aging Health. 1: 193-202. DOI: 10.2217/1745509X.1.2.193 |
0.398 |
|
| 2005 |
Stacy M. Apomorphine in Parkinson??s Disease Clinical Neuropharmacology. 28: 154. DOI: 10.1097/01.Wnf.0000171195.68116.D0 |
0.429 |
|
| 2004 |
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, ... ... Stacy M, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Archives of Neurology. 61: 1044-53. PMID 15262734 DOI: 10.1001/Archneur.61.7.1044 |
0.476 |
|
| 2004 |
Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology. 62: S22-6. PMID 15037668 DOI: 10.1212/Wnl.62.6_Suppl_4.S22 |
0.367 |
|
| 2004 |
Stacy M. Apomorphine: North American clinical experience Neurology. 62. PMID 15037667 DOI: 10.1212/Wnl.62.6_Suppl_4.S18 |
0.408 |
|
| 2004 |
Stacy M, Factor S. Rapid treatment of "off" episodes: Will this change Parkinson's disease therapy? Neurology. 62: S1-S2. DOI: 10.1212/Wnl.62.6_Suppl_4.S1 |
0.423 |
|
| 2003 |
Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, et al. A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study. Neurology. 61: 1557-61. PMID 14663042 DOI: 10.1212/01.Wnl.0000095966.99430.F4 |
0.357 |
|
| 2003 |
Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Lozano AM, Penn RD, Simpson RK, Stacy M, Wooten GF. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 60: 69-73. PMID 12525720 DOI: 10.1212/Wnl.60.1.69 |
0.431 |
|
| 2002 |
Shill H, Stacy M. Respiratory complications of Parkinson's disease. Seminars in Respiratory and Critical Care Medicine. 23: 261-265. PMID 16088618 DOI: 10.1055/S-2002-33034 |
0.406 |
|
| 2002 |
Siderowf A, Stern M, Shoulson I, Kieburtz K, Oakes D, Day D, Shinaman A, Plumb S, Fahn S, Blindauer K, Lew M, Hurtig H, Lloyd M, Hauser R, Gauger L, ... ... Stacy M, et al. A controlled trial of rasagiline in early Parkinson disease: The tempo study Archives of Neurology. 59: 1937-1943. PMID 12470183 DOI: 10.1001/Archneur.59.12.1937 |
0.501 |
|
| 2002 |
Baev KV, Greene KA, Marciano FF, Samanta JE, Shetter AG, Smith KA, Stacy MA, Spetzler RF. Physiology and pathophysiology of cortico-basal ganglia-thalamocortical loops: theoretical and practical aspects. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 26: 771-804. PMID 12188109 DOI: 10.1016/S0278-5846(02)00201-4 |
0.383 |
|
| 2002 |
DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, ... ... Stacy M, et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. American Journal of Human Genetics. 70: 1089-95. PMID 11920285 DOI: 10.1086/339814 |
0.406 |
|
| 2002 |
Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, ... ... Stacy M, et al. Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology. 58: 79-84. PMID 11781409 DOI: 10.1212/Wnl.58.1.79 |
0.411 |
|
| 2001 |
DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, Feldman RG, Guttman M, Watts RL, Suchowersky O, Lafontaine AL, Labelle N, Lew MF, Waters CH, Growdon JH, ... ... Stacy M, et al. Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology. 57: 1124-6. PMID 11571351 DOI: 10.1212/Wnl.57.6.1124 |
0.374 |
|
| 2000 |
Shill HA, Stacy MA. Malignant catatonia secondary to sporadic encephalitis lethargica Journal of Neurology, Neurosurgery, and Psychiatry. 69: 402-403. PMID 10991649 DOI: 10.1136/Jnnp.69.3.402 |
0.326 |
|
| 1998 |
Stacy M. Recognizing and Treating Nonmotor Disorders Associated with Parkinson's Disease Cns Spectrums. 3: 41-45. DOI: 10.1017/S1092852900005526 |
0.518 |
|
| 1998 |
Stacy M, Lou J. Making Headway—New Treatments in Parkinson's Disease Cns Spectrums. 3: 22-22. DOI: 10.1017/S1092852900005496 |
0.418 |
|
| 1993 |
Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias Neurology. 43: 937-941. PMID 8492949 DOI: 10.1212/Wnl.43.5.937 |
0.317 |
|
| 1993 |
Stacy M, Jankovic J. Current approaches in the treatment of Parkinson's disease. Annual Review of Medicine. 44: 431-440. PMID 8476262 DOI: 10.1146/Annurev.Me.44.020193.002243 |
0.469 |
|
| 1992 |
Stacy M, Jankovic J. Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. Neurologic Clinics. 10: 341-359. DOI: 10.1016/S0733-8619(18)30214-7 |
0.485 |
|
| Show low-probability matches. |